NCT02679196View on ClinicalTrials.gov

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 24, 2018

Study Completion Date

December 24, 2018

Conditions
Lymphoma, B Cell
Interventions
DRUG

KA2237

PI3 Kinase p110β/δ inhibitor

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Karus Therapeutics Limited

INDUSTRY